AVEO Pharmaceuticals (AVEO) Trading 11.9% Higher

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares traded up 11.9% during mid-day trading on Friday . The stock traded as high as $3.15 and last traded at $3.10. 3,615,965 shares changed hands during mid-day trading, an increase of 150% from the average session volume of 1,446,457 shares. The stock had previously closed at $2.77.

Several research analysts have issued reports on the company. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. B. Riley assumed coverage on AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price target on the stock. assumed coverage on AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, BidaskClub lowered AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $4.05.

The stock has a market cap of $366.80, a price-to-earnings ratio of -4.37 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33.

Large investors have recently made changes to their positions in the business. Fore Research & Management LP bought a new position in AVEO Pharmaceuticals in the second quarter worth approximately $111,000. Victory Capital Management Inc. bought a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $164,000. Rehmann Capital Advisory Group bought a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $193,000. OxFORD Asset Management LLP bought a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $228,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $550,000. Institutional investors and hedge funds own 50.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals (AVEO) Trading 11.9% Higher” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/01/14/aveo-pharmaceuticals-aveo-trading-11-9-higher.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

What are top analysts saying about AVEO Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AVEO Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit